Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070103 | 0.90 | BTK (0.76) | BTK | |
| SCHEMBL1065257 | 0.89 | BTK (0.64) | BTK | |
| SCHEMBL5240831 | 0.89 | BTK (0.78) | BTK | |
| SCHEMBL5242557 | 0.88 | BTK (0.64) | BTK | |
| SCHEMBL5280971 | 0.88 | BTK (0.70) | BTK | |
| SCHEMBL5918896 | 0.86 | BTK (0.61) | BTK | |
| SCHEMBL5281526 | 0.86 | BTK (0.62) | BTK | |
| SCHEMBL5918870 | 0.85 | BTK (0.59) | BTK | |
| SCHEMBL5237212 | 0.85 | BTK (0.59) | BTK | |
| SCHEMBL1068193 | 0.84 | BTK (0.59) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812442-A2 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | claimed |
| WO-2006053121-A2 | IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812442-A2 | IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006053121-A2 | IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | BTK, SYK, LCK | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.